Deeks, S.G. Antiretroviral treatment of HIV infected adults. Br. Med. J.332, 1489 (2006). Google Scholar
Phillips, A.N., Gazzard, B.G., Clumeck, N., Losso, M.H. & Lundgren, J.D. When should antiretroviral therapy for HIV be started? Br. Med. J.334, 76–78 (2007). Google Scholar
Sarver, N. et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science247, 1222–1225 (1990). CASPubMed Google Scholar
Michienzi, A. et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann. NY Acad. Sci.1002, 63–71 (2003). CASPubMed Google Scholar
Ngok, F.K. et al. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol. Biol.252, 581–598 (2004). CASPubMed Google Scholar
Bauer, G. et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1–infected donors using retroviral vectors containing anti–HIV-1 genes. Blood89, 2259–2267 (1997). CASPubMed Google Scholar
Leavitt, M.C. et al. Transfer of an anti–HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther.5, 1115–1120 (1994). CASPubMed Google Scholar
Chatterjee, S., Johnson, P.R. & Wong, K.K., Jr . Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science258, 1485–1488 (1992). CASPubMed Google Scholar
Levine, B.L. et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA103, 17372–17377 (2006). CASPubMedPubMed Central Google Scholar
Lu, X. et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1–based vector results in severely attenuated mutants incapable of developing resistance. J. Virol.78, 7079–7088 (2004). CASPubMedPubMed Central Google Scholar
Joshi, P.J., Fisher, T.S. & Prasad, V.R. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord.3, 383–400 (2003). CASPubMed Google Scholar
Symensma, T.L., Giver, L., Zapp, M., Takle, G.B. & Ellington, A.D. RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol.70, 179–187 (1996). CASPubMedPubMed Central Google Scholar
Kohn, D.B. et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34+ cells from the bone marrow of human immunodeficiency virus-1–infected children. Blood94, 368–371 (1999). CASPubMed Google Scholar
Hannon, G.J. & Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature431, 371–378 (2004). CASPubMed Google Scholar
Jacque, J.M., Triques, K. & Stevenson, M. Modulation of HIV-1 replication by RNA interference. Nature418, 435–438 (2002). CASPubMed Google Scholar
Lee, N.S. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol.20, 500–505 (2002). CASPubMed Google Scholar
Martinez, M.A., Clotet, B. & Este, J.A. RNA interference of HIV replication. Trends Immunol.23, 559–561 (2002). CASPubMed Google Scholar
Novina, C.D. et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med.8, 681–686 (2002). CASPubMed Google Scholar
Coburn, G.A. & Cullen, B.R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol.76, 9225–9231 (2002). CASPubMedPubMed Central Google Scholar
Boden, D., Pusch, O., Lee, F., Tucker, L. & Ramratnam, B. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol.77, 11531–11535 (2003). CASPubMedPubMed Central Google Scholar
Westerhout, E.M., Ooms, M., Vink, M., Das, A.T. & Berkhout, B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res.33, 796–804 (2005). CASPubMedPubMed Central Google Scholar
Das, A.T. et al. Human immunodeficiency virus type 1 escapes from RNA interference–mediated inhibition. J. Virol.78, 2601–2605 (2004). CASPubMedPubMed Central Google Scholar
Sabariegos, R., Gimenez-Barcons, M., Tapia, N., Clotet, B. & Martinez, M.A. Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J. Virol.80, 571–577 (2006). CASPubMedPubMed Central Google Scholar
Anderson, J. & Akkina, R. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology2, 53 (2005). PubMedPubMed Central Google Scholar
Cordelier, P., Morse, B. & Strayer, D.S. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV. Oligonucleotides13, 281–294 (2003). CASPubMed Google Scholar
Surabhi, R.M. & Gaynor, R.B. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol.76, 12963–12973 (2002). CASPubMedPubMed Central Google Scholar
An, D.S. et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol. Ther.14, 494–504 (2006). CASPubMed Google Scholar
Garred, P. et al. Dual effect of CCR5 delta 32 gene deletion in HIV-1–infected patients. Copenhagen AIDS Study Group. Lancet349, 1884 (1997). CASPubMed Google Scholar
Samson, M. et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature382, 722–725 (1996). CASPubMed Google Scholar
Huang. Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med.2:1240–1243 (1996). CASPubMed Google Scholar
Lapidot, T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2m null NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann. NY Acad. Sci.938, 83–95 (2001). CASPubMed Google Scholar
Lapidot, T. & Kollet, O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia16, 1992–2003 (2002). CASPubMed Google Scholar
Kahn, J. et al. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood103, 2942–2949 (2004). CASPubMed Google Scholar
Ariën, K.K. et al. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology347, 65–74. (2006). PubMed Google Scholar
Chang, L.J., Liu, X. & He, J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. Gene Ther.12, 1133–1144 (2005). CASPubMed Google Scholar
Berkhout, B. & Haasnoot, J. The interplay between virus infection and the cellular RNA interference machinery. FEBS Lett.580, 896–902 (2006). Google Scholar
Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature441, 537–541 (2006). CASPubMed Google Scholar
Li, M.J. et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther.12, 900–909 (2005). CASPubMed Google Scholar
Unwalla, H.J. et al. Novel Pol II fusion promoter directs human immunodeficiency virus type 1–inducible coexpression of a short hairpin RNA and protein. J. Virol.80, 1863–1873 (2006). CASPubMedPubMed Central Google Scholar
Woffendin, C., Ranga, U., Yang, Z., Xu, L. & Nabel, G.J. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus–infected patients. Proc. Natl. Acad. Sci. USA93, 2889–2894 (1996). CASPubMedPubMed Central Google Scholar
Lobato, M.N. & Rabbitts, T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med.4, 519–528 (2004). CASPubMed Google Scholar
Marasco, W.A., LaVecchio, J. & Winkler, A. Human anti–HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods231, 223–238 (1999). CASPubMed Google Scholar
Poluri, A., van Maanen, M. & Sutton, R.E. Genetic therapy for HIV/AIDS. Expert Opin. Biol. Ther.3, 951–963 (2003). CASPubMed Google Scholar
Schroers, R., Davis, C.M., Wagner, H.J. & Chen, S.Y. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther.9, 889–897 (2002). CASPubMed Google Scholar
Yang, A.G., Bai, X., Huang, X.F., Yao, C. & Chen, S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc. Natl. Acad. Sci. USA94, 11567–11572 (1997). CASPubMedPubMed Central Google Scholar
Egelhofer, M. et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J. Virol.78, 568–575 (2004). CASPubMedPubMed Central Google Scholar
Perez, E.E., Riley, J.L., Carroll, R.G., von Laer, D. & June, C.H. Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. Clin. Immunol.115, 26–32 (2005). CASPubMed Google Scholar
Mani, M., Kandavelou, K., Dy, F.J., Durai, S. & Chandrasegaran, S. Design, engineering, and characterization of zinc finger nucleases. Biochem. Biophys. Res. Commun.335, 447–457 (2005). CASPubMed Google Scholar
Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol.25, 1298–1306 (2007). CASPubMed Google Scholar
Levine, B.L. et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science272, 1939–1943 (1996). CASPubMed Google Scholar
Levine, B.L. et al. Effects of CD28 costimulation on long term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol.159, 5921–5930 (1997). CASPubMed Google Scholar
Carroll, R.G. et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science276, 273–276 (1997). CASPubMed Google Scholar
Bex, F. et al. Syngeneic adoptive transfer of anti–human immunodeficiency virus-1 (HIV-1)–primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1–infected identical twin. Blood84, 3317–3326 (1994). CASPubMed Google Scholar
Levine, B.L. et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med.8, 47–53 (2002). CASPubMed Google Scholar
Fearon, D.T., Manders, P. & Wagner, S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science293, 248–250 (2001). CASPubMed Google Scholar
Barber, D.L., Wherry, E.J. & Ahmed, R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol.171, 27–31 (2003). CASPubMed Google Scholar
Muul, L.M. et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood101, 2563–2569 (2003). CASPubMed Google Scholar
Lund, O. et al. Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull. Math. Biol.59, 725–745 (1997). CASPubMed Google Scholar
von Laer, D., Hasselmann, S. & Hasselmann, K. Impact of gene-modified T cells on HIV infection dynamics. J. Theor. Biol.238, 60–77 (2006). CASPubMed Google Scholar
Weinberger, L.S., Schaffer, D.V. & Arkin, A.P. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol.77, 10028–10036 (2003). CASPubMedPubMed Central Google Scholar
Lalezari, J.P. et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir. Ther.8, 279–287 (2003). CASPubMed Google Scholar
van Lunzen, J. et al. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther.15, 1024–1033 (2007). CASPubMed Google Scholar
Masiero, S. et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther.12, 299–310 (2005). CASPubMed Google Scholar
Briz, V., Poveda, E. & Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother.57, 619–627 (2006). CASPubMed Google Scholar
Strayer, D.S. et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther.11, 823–842 (2005). CASPubMed Google Scholar
Swan, C.H. & Torbett, B.E. Can gene delivery close the door to HIV-1 entry after escape? J. Med. Primatol.35, 236–247 (2006). CASPubMed Google Scholar
Luis, A.J. et al. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol. Ther.8, 475–484 (2003). Google Scholar
Swan, C.H., Buhler, B., Tschan, M.P., Barbas, C.F., III & Torbett, B.E. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther.13, 1480–1492 (2006). CASPubMed Google Scholar
Bai, J. et al. Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J. Biol. Chem.278, 1433–1442 (2003). CASPubMed Google Scholar
BouHamdan, M. et al. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4. Gene Ther.8, 408–418 (2001). CASPubMed Google Scholar
Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature427, 848–853 (2004). CASPubMed Google Scholar
Luban, J. & Cyclophilin, A. TRIM5, and resistance to human immunodeficiency virus type 1 infection. J. Virol.81, 1054–1061 (2007). CASPubMed Google Scholar
Li, Y., Li, X., Stremlau, M., Lee, M. & Sodroski, J. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol.80, 6738–6744 (2006). CASPubMedPubMed Central Google Scholar
Ranga, U. et al. Retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl. Acad. Sci. USA95, 1201–1206 (1998). CASPubMedPubMed Central Google Scholar
Morgan, R.A. et al. Preferential survival of CD4+ T lymphocytes engineered with anti–human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum. Gene Ther.16, 1065–1074 (2005). CASPubMed Google Scholar
Macpherson, J.L. et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J. Gene Med.7, 552–564 (2005). CASPubMed Google Scholar
Amado, R.G. et al. Anti–human immunodeficiency virus hematopoietic progenitor cell–delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1–infected patients. Hum. Gene Ther.15, 251–262 (2004). CASPubMed Google Scholar
VandenDriessche, T. et al. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J. Virol.69, 4045–4052 (1995). CASPubMedPubMed Central Google Scholar
Veres, G. et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J. Virol.72, 1894–1901 (1998). CASPubMedPubMed Central Google Scholar
Humeau, L.M. et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther.9, 902–913 (2004). CASPubMed Google Scholar
Schroder, A.R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell110, 521–529 (2002). CASPubMed Google Scholar
Sadelain, M. Insertional oncogenesis in gene therapy: how much of a risk? Gene Ther.11, 569–573 (2004). CASPubMed Google Scholar
Li, M.J. et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III–promoted anti-HIV RNAs. Mol. Ther.8, 196–206 (2003). CASPubMed Google Scholar
Eberhardy, S.R. et al. Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J. Virol.80, 2873–2883 (2006). CASPubMedPubMed Central Google Scholar
Kiepiela, P. et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med.13, 46–53 (2007). CASPubMed Google Scholar
Walter, E.A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med.333, 1038–1044 (1995). CASPubMed Google Scholar
Heslop, H.E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus–specific T lymphocytes. Nat. Med.2, 551–555 (1996). CASPubMed Google Scholar
Brodie, S.J. et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest.105, 1407–1417 (2000). CASPubMedPubMed Central Google Scholar
Wodarz, D. & Nowak, M.A. Specific therapy regimes could lead to long-term immunological control of HIV. Proc. Natl. Acad. Sci. USA96, 14464–14469 (1999). CASPubMedPubMed Central Google Scholar
Roberts, M.R. et al. Targeting of human immunodeficiency virus–infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood84, 2878–2889 (1994). CASPubMed Google Scholar
Yang, O.O. et al. Lysis of HIV-1–infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl. Acad. Sci. USA94, 11478–11483 (1997). CASPubMedPubMed Central Google Scholar
Walker, R.E. et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood96, 467–474 (2000). CASPubMed Google Scholar
Mitsuyasu, R.T. et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus–infected subjects. Blood96, 785–793 (2000). CASPubMed Google Scholar
Deeks, S.G. et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination anti-retroviral therapy. Mol. Ther.5, 788–797 (2002). CASPubMed Google Scholar
Letvin, N.L. & Walker, B.D. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat. Med.9, 861–866 (2003). CASPubMed Google Scholar
Cooper, L.J., Kalos, M., Lewinsohn, D.A., Riddell, S.R. & Greenberg, P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol.74, 8207–8212 (2000). CASPubMedPubMed Central Google Scholar
Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314, 126–129 (2006). CASPubMedPubMed Central Google Scholar
Holler, P.D., Lim, A.R., Cho, B.K., Rund, L.A. & Kranz, D.M. CD8− T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J. Exp. Med.194, 1043–1052 (2001). CASPubMedPubMed Central Google Scholar
Li, Q.J. et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell129, 147–161 (2007). CASPubMed Google Scholar
Boulter, J.M. et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng.16, 707–711 (2003). CASPubMed Google Scholar
Shultz, L.D., Ishikawa, F. & Greiner, D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol.7, 118–130 (2007). CASPubMed Google Scholar
Berges, B.K. et al. HIV-1 infection and Cd4 T cell depletion in the humanized Rag2−/−gamma c−/− (RAG-hu) mouse model. Retrovirology3, 76 (2006). PubMedPubMed Central Google Scholar
van Baarle, D., Tsegaye, A., Miedema, F., & Akbar, A. Significance of senescence for virus-specific memory T cell responses: rapid ageing during chronic stimulation of the immune system. Immunol. Lett.97, 19–29 (2005). CASPubMed Google Scholar
Kaech, S.M., Hemby, S., Kersh, E. & Ahmed, R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell111, 837–851 (2002). CASPubMed Google Scholar
Mazurier, F. et al. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood103, 545–552 (2004). CASPubMed Google Scholar
Check, E. Pioneering HIV treatment would use interference and gene therapy. Nature437, 601 (2005). CASPubMed Google Scholar
Bahner, I. et al. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther.15, 76–85 (2007). CASPubMed Google Scholar
Bahner, I., Kearns, K., Hao, Q.L., Smogorzewska, M. & Kohn, D.B. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits HIV-1 replication in the myelomonocytic cells produced in long-term culture. J. Virol.70, 4352–4360 (1996). CASPubMedPubMed Central Google Scholar
Rosenzweig, M. et al. Intracellular immunization of rhesus CD34+ hematopoietic progenitor cells with a hairpin ribozyme protects T cells and macrophages from simian immunodeficiency virus infection. Blood90, 4822–4831 (1997). CASPubMed Google Scholar
Davis, B.R. et al. Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages. Hum. Gene Ther.9, 1197–1207 (1998). CASPubMed Google Scholar
Braun, S.E. et al. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Mol. Ther.12, 1157–1167 (2005). CASPubMed Google Scholar
Su, L. et al. Hematopoietic stem cell–based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood89, 2283–2290 (1997). CASPubMed Google Scholar
Bai, J. et al. RNA-based anti–HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther.6, 770–782 (2002). CASPubMed Google Scholar
Anderson, J. et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes—CCR5 ribozyme, tat-rev siRNA, and TAR decoy—in SCID-hu mouse-derived T cells. Mol. Ther.15, 1182–1188 (2007). CASPubMed Google Scholar
An, D.S. et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. USA104, 13110–13115 (2007). CASPubMedPubMed Central Google Scholar
Zaia, J.A. et al. Autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected persons: comparison of gene marking post-engraftment with and without myeloablative therapy. Blood94 Suppl 1, 642a (1999). Google Scholar
Amado, R.G. et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum. Gene Ther.10, 2255–2270 (1999). CASPubMed Google Scholar
Podsakoff, G.M. et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34+ cells. Mol. Ther.12, 77–86 (2005). CASPubMed Google Scholar
Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science296, 2410–2413 (2002). CASPubMed Google Scholar
Ott, M.G. et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1–EVI1, PRDM16 or SETBP1. Nat. Med.12, 401–409 (2006). CASPubMed Google Scholar
Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science288, 669–672 (2000). CASPubMed Google Scholar
Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science302, 415–419 (2003). CASPubMed Google Scholar
Payne, K.J. & Crooks, G.M. Immune-cell lineage commitment: translation from mice to humans. Immunity26, 674–677 (2007). CASPubMed Google Scholar
Wong-Staal, F., Poeschla, E.M. & Looney, D.J. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther.9, 2407–2425 (1998). CASPubMed Google Scholar
Kang, E.M. et al. Gene therapy–based treatment for HIV-positive patients with malignancies. J. Hematother. Stem Cell Res.11, 809–816 (2002). CASPubMed Google Scholar
Barrett, A.D. & Dimmock, N.J. Defective interfering viruses and infections of animals. Curr. Top. Microbiol. Immunol.128, 55–84 (1986). CASPubMed Google Scholar
Roux, L., Simon, A.E. & Holland, J.J. Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv. Virus Res.40, 181–211 (1991). CASPubMedPubMed Central Google Scholar
Mautino, M.R. & Morgan, R.A. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther.9, 421–431 (2002). CASPubMed Google Scholar